Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Launches $5M Private Financing

NEW YORK (GenomeWeb) – Cancer Genetics has entered into definitive agreements for a $5 million registered direct offering and will concurrently issue unregistered warrants to the investors.

The Rutherford, NJ-based diagnostics firm will sell 2.5 million shares of common stock to institutional investors. For each share of common stock purchased, investors will receive a warrant to purchase one half-share of common stock. The warrants have an exercise price of $2.25 per share and will be exercisable six months from the date of issuance, expected to be May 25, subject to closing conditions. The warrants expire five years after the initial exercise date.

Cancer Genetics expects to receive net proceeds of $4.5 million, which will be used for general corporate purposes.

As of March 31, the firm had $13.3 million in cash and cash equivalents.

Rodman & Renshaw acted as exclusive placement agent.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.